CANFOUR clinical results, interview

To the interview (in Swedish)

Cantargia listed on Nasdaq Stockholm (Small Cap)

Read more

Two Nobel Prizes with utmost significance for Cantargia’s research

Read more

The new generation of cancer treatments

Cantargia's CAN04 antibody treatment fights cancer by activating the immune system, and by blocking signals that lead to tumour growth.

Read more

Development of new antibody-based cancer treatments

Read more

Latest press releases

(R) Cantargia publishes interim report for third quarter of 2018

(R) Cantargia AB: Nomination Committee appointed ahead of 2019 Annual General Meeting

(R) Cantargia presented positive phase I clinical data with lead candidate CAN04 at ESMO

* (R) = Regulatory press releases

Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.

Cantargia is since September 25, 2018 listed on Nasdaq Stockholm main market (Small Cap).

How CAN04 attacks a cancer tumour

Watch the animated video